Testosterone-replacement therapy does not increase cardiac events in men with hypogonadism

Testosterone-replacement therapy in men with hypogonadism and a high risk of cardiovascular disease does not increase the risk of adverse cardiac events, according to data from the TRAVERSE trial.

Automated summary

Data from the TRAVERSE trial suggests that testosterone-replacement therapy in men with hypogonadism and a high risk of cardiovascular disease does not pose an increased risk of adverse cardiac events.